Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) EBIT Margin (2024 - 2025)

Prime Medicine filings provide 2 years of EBIT Margin readings, the most recent being 5800.48% for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 377473.0% to 5800.48% in Q4 2025 year-over-year; TTM through Dec 2025 was 4498.06%, a 228930.0% increase, with the full-year FY2025 number at 4498.06%, up 228930.0% from a year prior.
  • EBIT Margin hit 5800.48% in Q4 2025 for Prime Medicine, down from 4405.96% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 2025.74% in Q4 2024 to a low of 25948.33% in Q3 2024.